Insulinoma in childhood: clinical, radiological, molecular and histological aspects of nine patients

BACKGROUND

Insulinomas are a rare cause of hyperinsulinaemic hypoglycaemia (HH) in children. The clinical features, investigations, management and histology of these rare pancreatic tumours in children have not been described in a large cohort of patients.

METHODS

We conducted a retrospective review of cases diagnosed between 2000 and 2012, presenting to two referral centres in the United Kingdom. Clinical, biochemical, imaging (magnetic resonance imaging (MRI) and 6-L-¹⁸F-fluorodihydroxyphenylalanine (¹⁸F-DOPA) PET/CT scanning) and histological data were collected.

RESULTS

Nine children (age range 2-14.5 years) were diagnosed during the study period at Great Ormond Street Hospital (n=5) and Royal Manchester Children's Hospital (n=4). The combination of abdominal MRI scan (7/8) and ¹⁸F-DOPA PET/CT scan (2/4) correctly localised the anatomical location of all insulinomas. Before surgery, diazoxide therapy was used to treat hypoglycaemia, but only four patients responded. After surgical resection of the insulinoma, hypoglycaemia resolved in all patients. The anatomical localisation of the insulinoma in each patient was head (n=4), uncinate process (n=4) and tail (n=2, one second lesion) of the pancreas. Histology confirmed the diagnosis of insulinoma with the presence of sheets and trabeculae of epithelioid and spindle cells staining strongly for insulin and proinsulin, but not for glucagon or somatostatin. Two children were positive for MEN1, one of whom had two separate insulinoma lesions within the pancreas.

CONCLUSIONS

We describe a cohort of paediatric insulinoma patients. Although rare, insulinomas should be included in the differential diagnosis of HH, even in very young children. In the absence of a single imaging modality in the preoperative period, localisation of the tumour is achieved by combining imaging techniques, both conventional and functional.

Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer

Background

There is no method routinely used to predict response to anthracycline and cyclophosphamide–based chemotherapy in the clinic; therefore patients often receive treatment for breast cancer with no benefit. Loss of the Fanconi anemia/BRCA (FA/BRCA) DNA damage response (DDR) pathway occurs in approximately 25% of breast cancer patients through several mechanisms and results in sensitization to DNA-damaging agents. The aim of this study was to develop an assay to detect DDR-deficient tumors associated with loss of the FA/BRCA pathway, for the purpose of treatment selection.

Methods

DNA microarray data from 21 FA patients and 11 control subjects were analyzed to identify genetic processes associated with a deficiency in DDR. Unsupervised hierarchical clustering was then performed using 60 BRCA1/2 mutant and 47 sporadic tumor samples, and a molecular subgroup was identified that was defined by the molecular processes represented within FA patients. A 44-gene microarray-based assay (the DDR deficiency assay) was developed to prospectively identify this subgroup from formalin-fixed, paraffin-embedded samples. All statistical tests were two-sided.

Results

In a publicly available independent cohort of 203 patients, the assay predicted complete pathologic response vs residual disease after neoadjuvant DNA-damaging chemotherapy (5-fluorouracil, anthracycline, and cyclophosphamide) with an odds ratio of 3.96 (95% confidence interval [Cl] =1.67 to 9.41; P = .002). In a new independent cohort of 191 breast cancer patients treated with adjuvant 5-fluorouracil, epirubicin, and cyclophosphamide, a positive assay result predicted 5-year relapse-free survival with a hazard ratio of 0.37 (95% Cl = 0.15 to 0.88; P = .03) compared with the assay negative population.

Conclusions

A formalin-fixed, paraffin-embedded tissue-based assay has been developed and independently validated as a predictor of response and prognosis after anthracycline/cyclophosphamide–based chemotherapy in the neoadjuvant and adjuvant settings. These findings warrant further validation in a prospective clinical study.

Integrating molecular diagnostics into histopathology training: the Belfast model

Molecular medicine is transforming modern clinical practice, from diagnostics to therapeutics. Discoveries in research are being incorporated into the clinical setting with increasing rapidity. This transformation is also deeply changing the way we practise pathology. The great advances in cell and molecular biology which have accelerated our understanding of the pathogenesis of solid tumours have been embraced with variable degrees of enthusiasm by diverse medical professional specialties. While histopathologists have not been prompt to adopt molecular diagnostics to date, the need to incorporate molecular pathology into the training of future histopathologists is imperative. Our goal is to create, within an existing 5-year histopathology training curriculum, the structure for formal substantial teaching of molecular diagnostics. This specialist training has two main goals: (1) to equip future practising histopathologists with basic knowledge of molecular diagnostics and (2) to create the option for those interested in a subspecialty experience in tissue molecular diagnostics to pursue this training. It is our belief that this training will help to maintain in future the role of the pathologist at the centre of patient care as the integrator of clinical, morphological and molecular information.

Poly(vinylidene fluoride)–La0.5Sr0.5CoO3−δ composites: the influence of LSCO particle size on the structure and dielectric properties

The inclusion of LSCO into PVDF readily favours the formation of polar crystals (β and γ-phases), which makes the composite suitable for embedded capacitor applications.

Increasing awareness of hypoglycaemia in patients with type 2 diabetes treated with oral agents

Hypoglycaemia is the most common acute complication of type 2 diabetes and can limit therapeutic efforts to improve glycaemic control in order to protect against long-term complications. It is a potential side effect of the drugs used to treat diabetes, specifically exogenous insulin or insulin secretagogues. As many people are prescribed these agents, hypoglycaemia is frequent in clinical practice, although patients commonly do not inform their healthcare professional of the problems spontaneously. The impact of hypoglycaemia on the patient and to the healthcare system is significant through reduced treatment satisfaction and adherence, reduced quality of life and serious health consequences. This has financial implications and costs for the patient, the public and the economy at large. The single most important risk factor for hypoglycaemia is previous hypoglycaemia. Prevention depends on appropriate education regarding diabetes management and selfcare, self-monitoring of blood glucose, awareness of factors that may precipitate hypoglycaemia, and an individualized approach to therapy and glycaemic control targets. The purpose of this review is to increase understanding of the impact and consequences of hypoglycaemia, in particular that associated with sulphonylurea therapy, and to highlight areas requiring more attention in order to improve the overall management of people with type 2 diabetes.

Study on the mechanical and environmental properties of concrete containing cathode ray tube glass aggregate

Cathode ray tube (CRT) glass is considered a hazardous material due to its lead toxicity. In addition, current disposal practices are being phased out due to their adverse environmental impacts. In this project, CRT glass was used as a fine aggregate replacement in concrete. Life-cycle material characterization was conducted by evaluating the durability and strength of the CRT-Concrete. Leaching tests were also conducted to investigate whether the material meets drinking water limits for Pb. Test results show that the plastic state of the CRT-Concrete was affected by the angularity of the glass particles. Moreover, the compressive strength of CRT-Concrete met and exceeded that of the control specimen. However, CRT-Concrete was susceptible to expansive alkali-silica reactions when more than 10% CRT replacement was used. Environmental leaching results show that lead concentrations from CRT-Concrete are below the drinking water limits depending on the CRT volume replacement and if biopolymers are used.

Determining in-patient diabetes treatment satisfaction in the UK--the DIPSat study

AIMS

To measure in-patient diabetes treatment satisfaction and its relationship to in-patient diabetes care.

METHODS

In a cross-sectional study, diabetes in-patient specialist nurses at 58 UK hospitals asked insulin-treated in-patients with diabetes to complete the recently updated Diabetes Treatment Satisfaction Questionnaire for In-patients and a general questionnaire; 1319 in-patients completed these questionnaires.

RESULTS

Satisfaction with the general diabetes treatment items in the Diabetes Treatment Satisfaction Questionnaire for In-patients was high, but there were high levels of extreme dissatisfaction with meal choices, meal quality and lack of similarity of hospital meals to normal domestic choices--23% would never or rarely have made similar meal choices at home. Hyperglycaemia or hypoglycaemia was reported for much of the in-patient stay (20% and 7%, respectively) and 26% reported at least one severe hypoglycaemic episode; these groups had lower satisfaction with the timing of medication in relation to meals (P < 0.003). More frequent in-patient hyperglycaemia or hypoglycaemia were associated with significantly poorer overall satisfaction scores and negative well-being scores (both P < 0.0001). Previous experience of a multiple daily insulin injection regimen was associated with more dissatisfaction than other regimens (P < 0.01). Multiple regression models explained 36% of variability in overall treatment satisfaction, with most (22.4%) accounted for by satisfaction with time spent with a diabetes in-patient specialist nurse (P < 0.0001). Self-administration of insulin was independently associated with higher treatment satisfaction (P < 0.006) in this model.

CONCLUSIONS

The DIPSat programme describes the complex relationships between diabetes in-patient treatment satisfaction and in-patient diabetes care.

Identification and validation of an assay predictive of response and prognosis following anthracycline-based chemotherapy for early breast cancer

TPS11120

Background: Currently there is no biomarker to predict specific benefit from DNA-damaging anthracycline and cyclophosphamide-based chemotherapy in the clinic. Loss of the Fanconi anemia/BRCA (FA/BRCA) DNA-damage response pathway occurs in approximately 25% of breast cancer and results in sensitivity to DNA-damaging agents. We therefore developed an assay to detect loss of the FA/BRCA pathway, for the purpose of predicting benefit from chemotherapy. Methods: 21 FA patient samples were analyzed to identify genetic processes associated with loss of the FA/BRCA pathway. Unsupervised hierarchical clustering was then performed using 60 BRCA1/2 mutant and 47 sporadic tumor samples and a molecular subgroup was identified that was defined by the molecular processes representing loss of the FA/BRCA pathway. A 44-gene DNA Damage response deficient (DDRD) assay was developed that could identify this subgroup from formalin fixed, paraffin embedded (FFPE) samples in the clinic. Results: In a publicly available independent cohort of 204 patients, the assay predicted response to neoadjuvant DNA-damaging chemotherapy (5-fluorouracil, anthracycline and cyclophosphamide) with an odds ratio of 4.01, (95% Cl:1.69-9.54). We also analysed samples from an independent cohort of 114 node-negative breast cancer patients treated with adjuvant 5-fluorouracil, epirubicin and cyclophosphamide treatment at the Northern Ireland Cancer Centre. The DDRD assay significantly predicted 5-year relapse free survival with a hazard ratio of 0.27 (95% Cl:0.10-0.83). The assay was not predictive of survival in patients who did not receive chemotherapy. Conclusions: An FFPE tissue-based assay that detects loss of the FA/BRCA pathway has been developed and independently validated as a predictor of response and prognosis following DNA damaging anthracycline/cyclophosphamide-based chemotherapy in the neoadjuvant and adjuvant settings.

Immunohistochemistry in the era of personalised medicine

BACKGROUND

Immunohistochemistry (IHC) plays a central role in the histopathological classification of diseases, including cancer. More recently, the importance of immunohistochemical staining is increasing. IHC usage in diagnostics is invaluable; however, the genetic and therapeutic significance of biomarker immunostaining has become equally relevant.

CONTENT

In this article, we would like to analyse the three distinct roles of IHC and review their individual impacts on modern diagnostic pathology: (1) diagnostic IHC; (2) genetic IHC and (3) therapeutic IHC.

SUMMARY

Thus, we will characterise the different analytical processes that are required in the three approaches to IHC usage stated above, as well as the clinical significance and overall importance in patient management. This will allow us to hypothesise on the most appropriate laboratory environment and detection methods for the future.

Attenuation correction of myocardial perfusion SPET in patients of normal body mass index

Soft tissue attenuation artefacts are more likely to occur in patients with high body mass index (BMI) undergoing myocardial perfusion imaging (MPI) and therefore it is routine practice in our department to perform attenuation correction in this group of patients. However, we suspected that attenuation artefacts may also occur in patients with normal BMI. We collected data prospectively on 57 patients with BMI less than 25kg/m(2) who underwent stress-rest MPI single photon emission tomography (SPET) as part of their standard management at our institution. The differences between the attenuation corrected (AC) and non attenuation corrected (NC) images were evaluated by two experienced readers blinded to patient gender and clinical details. Visual improvement in perfusion with attenuation correction was seen in 54.4% of patients with normal BMI and was more common in males (84.2%) than females (39.5%). Discordances between AC and NC were most frequent in the inferior, inferolateral and anteroseptal segments in both males and females and were also seen in the apical and anterior segments in some patients, mainly in females, in keeping with the well-recognized distribution pattern for attenuation artefacts. In conclusion, although a small sample size was used in this study, changes in appearance with attenuation correction likely to represent attenuation artefacts were seen in 54.4% of patients with normal BMI and were two times more common in males than females. These changes were felt to be clinically relevant in that they could lead to a change in the final report and may ultimately affect the diagnosis and clinical management. Thus, attenuation correction could be of value in patients of normal BMI. Further larger studies with correlation with clinical follow-up or invasive coronary angiography are warranted.

Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis

Human Papillomavirus (HPV) related oropharyngeal squamous cell carcinomas (OPSCCs) are reported to have improved prognosis and survival in comparison to other head and neck squamous cell cancers (HNSCCs). This systematic review and meta-analysis examines survival differences in HPV-positive HNSCC and OPSCC subtypes including tonsillar carcinoma in studies not previously investigated. Four electronic databases were searched from their inception till April 2011. A random effects meta-analysis was used to pool study estimates evaluating disease-specific (death from HNSCC), overall (all-cause mortality), progression-free and disease-free (recurrence free) survival outcomes in HPV-positive vs. HPV-negative HNSCCs. All statistical tests were two-sided. Forty-two studies were included. Patients with HPV-positive HNSCC had a 54% better overall survival compared to HPV-negative patients HR 0.46 (95% CI 0.37-0.57); the pooled HR for tonsillar cancer and OPSCC was 0.50 (95% CI 0.33-0.77) and HR 0.47 (95% CI 0.35-0.62) respectively. The pooled HR for disease specific survival was 0.28 (95% CI 0.19-0.40); similar effect sizes were found irrespective of the adjustment for confounders, HPV detection methods or study location. Both progression-free survival and disease-free survival were significantly improved in HPV-positive HNSCCs. HPV-positive HNSCCs and OPSCCs patients have a significantly lower disease specific mortality and are less likely to experience progression or recurrence of their cancer than HPV-negative patients; findings which have connotations for treatment selection in these patients.

SU-E-I-67: Multi-Shot RESOLVE Compared to Single-Shot EPI Diffusion- Weighted MR Imaging Acquisition Scheme

PURPOSE

The purpose of this project was to configure the parameters for optimal comparison of image quality differences between the prototype imaging technique, read-out-segmented EPI multi-shot (RESOLVE) and the clinically used single-shot EPI (SS-EPI) MRI sequence for Diffusion Weighted Imaging (DWI) in a saline phantom, followed by a normal rat brain.

METHODS

Saline phantom (4.2 × 4.2 cm² ) and a rat brain were imaged on the 1.5T ESPREE (Siemens, Germany) MRI magnet using a wrist coil. Both the SS-EPI and RESOLVE DWI were optimized with equal imaging parameters such as slice thickness/slice gap = 3.0/0 mm, field of view = 210 mm, phase resolution = 100%, and diffusion b values = 0, 600 s/mm² while other parameters were given similar settings such as the base resolution, which had to be interpolated for the SS-EPI to 96i to match the RESOLVE as it was unable to be set at 192. Image quality was compared in terms of signal intensity, distortion, % ghosting and Apparent Diffusion Co-efficient (ADC) measurements from each sequence.

RESULTS

A marked enhancement of overall image quality with superior detail was observed in each of the scans from the RESOLVE sequence when compared to the SS-EPI. Comparing the efficiency of both sequences in terms of image quality, RESOLVE demonstrated a better stable image with minimal distortion and ghosting. The phantom dimensions obtained from RESOLVE images matched the actual dimensions perfectly. RESOLVE images had signal intensities significantly higher than (2.4×) the SS-EPI images (p=0.0008) and ∼0.6 % times less ghosting compared to SS-EPI (p=0.82) which also exhibited distortion with reduced phantom dimensions (4.05 × 3.28 cm) from original. The ADC values computed were almost identical to be (p=0.32) from SS-EPI (2.21mm² /sec) and RESOLVE (2.19mm² /sec).

CONCLUSIONS

The RESOLVE sequence has significantly superior image quality compared to SS-EPI at 1.5 T with reasonable scan times. DWI with RESLOVE acquisition scheme can be highly beneficial in obtaining distortion free images in routine clinical studies to characterize tumors and other pathological mechanisms with much greater detail than the current clinically used SS-EPI.

A study of brain and serum brain-derived neurotrophic factor protein in Wistar and Wistar-Kyoto rat strains after electroconvulsive stimulus

BACKGROUND

Serum brain-derived neurotrophic factor (BDNF) protein has been related to depression and less consistently to its treatments in human studies. However, animal studies have failed to demonstrate a clear link between BDNF protein in serum and brain tissue.

METHODS

Serum and brain tissue levels of BDNF protein were measured with ELISA in the Wistar-Kyoto (WKY) and Wistar strains at 1 and 7 days after 5 daily electroconvulsive stimulus sessions or sham treatments.

RESULTS

The WKY strain showed lower baseline serum BDNF protein relative to Wistar controls. After 5 electroconvulsive stimuli, BDNF protein density was significantly increased in hippocampus and cortical regions, but not in the cerebellum or in serum. A clear correlation between brain and serum BDNF was not observed in either strain or treatment group.

DISCUSSION

Despite lower baseline serum BDNF protein in the WKY strain, a lack of change in serum BDNF after electroconvulsive stimulus and a lack of correlation between brain and serum BDNF protein calls into question the relevance of serum BDNF as a measure of depression and treatment response.

Investigations into the molecular-level adhesion characteristics of hydroxyapatite-coated and anodized titanium surfaces using the molecular orbital approach

It has been established that the adhesion of cells on to the surfaces of orthopaedic implants depends on the ability of the surfaces to accommodate protein molecules. Hydroxyapatite coating and anodizing are the most common methods to make TiAl6V4 implants (Ti) more biocompatible. In this paper Spartan 02, a molecular dynamics software, is used to analyze and predict the bonding characteristics of Extra cellular matrix protein sequence arginine-glycine-aspartic acid (RGD) on a Hyrdoxyapatite (HA) coated Ti and an anodized Ti surface based on the property of its constituent atoms, their polarity (net electrostatic charge, Qr), the energies of the molecular orbital E_HOMO (energy of the highest occupied molecular orbital), and E_LUMO (energy of the lowest unoccupied molecular orbital). The results show favourable criterion for formation of bonding between the HOMO orbital of the HA coated and anodized surfaces and LUMO orbital of the glycine strand from the RGD unit. The mechanism of bonding of individual atoms to form primary calcium oxide compounds is likely only in the case of HA coated surfaces . The surface texture of the anodized Ti with inherent porosities appear more responsible for the adsorption of proteins on to them by mechanical interlocking than the formation of any intermediate calcium oxide compounds.

Polycrystalline coating of hydroxyapatite on TiAl6V4 implant material grown at lower substrate temperatures by hydrothermal annealing after pulsed laser deposition

Hydroxyapatite (HA) is a bioactive ceramic material that mimics the mineral composition of natural bone. This material does not possess acceptable mechanical properties for use as a bulk biomaterial; however, it does demonstrate significant potential for use as a coating on metallic orthopaedic and dental prostheses. Pulsed laser deposition (PLD) of thin films of HA on TiAl6V4 have shown crystalline coatings to be obtained at temperatures of the order of 350-500 degrees C. This condition of high substrate temperature promoted the oxidation of the substrate surface prior to the growth of the HA layer and the oxidation layer degraded the adhesion of the coating to the substrate. In this study, thin films of HA were deposited on TiAl6V4 alloy at a lower temperature of 200 degrees C by PLD and crystallized by a hydrothermal treatment at 100 degrees C. The film was subjected to mechanical as well as cell viability tests in vitro. The thickness, roughness, crystallanity, composition ratio, adhesive strength, and cell adhesion of the film suggest the application of this technique for producing bioactive implants.

A national survey of the current state of screening services for diabetic retinopathy: ABCD-diabetes UK survey of specialist diabetes services 2006

The main aims were to ascertain the progress made in the implementation of retinal screening services and to explore any barriers or difficulties faced by the programmes. The survey focused on all the essential elements for retinal screening, including assessment and treatment of screen-positive cases. Eighty-five per cent of screening programmes have a coordinated screening service and 73% of these felt that they have made significant progress. Eighty-five per cent of screening units use 'call and recall' for appointments and 73.5% of programmes follow the National Screening Committee (NSC) guidance. Although many units worked closely with ophthalmology, further assessment and management of screen-positive patients was a cause for concern. The fast-track referral system, to ensure timely and appropriate care, has been difficult to engineer by several programmes. This is demonstrated by 48% of programmes having waiting lists for patients identified as needing further assessment and treatment for retinopathy. Ophthalmology service for people with diabetic retinopathy was provided by a dedicated ophthalmologist in 89.4% of the programmes. Sixty-six per cent of the programmes reported inadequate resources to sustain a high-quality service, while 26% highlighted the lack of infrastructure and 49% lacked information technology (IT) support. In conclusion, progress has been made towards establishing a national screening programme for diabetic retinopathy by individual screening units, with a number of programmes providing a structured retinal screening service. However, programmes face difficulties with resource allocation and compliance with Quality Assurance (QA) standards, especially those which apply to ophthalmology and IT support. Screening programmes need to be resourced adequately to ensure comprehensive coverage and compliance with QA.